PT2442832E - Composições e métodos para tratamento da esclerose múltipla - Google Patents
Composições e métodos para tratamento da esclerose múltipla Download PDFInfo
- Publication number
- PT2442832E PT2442832E PT107897886T PT10789788T PT2442832E PT 2442832 E PT2442832 E PT 2442832E PT 107897886 T PT107897886 T PT 107897886T PT 10789788 T PT10789788 T PT 10789788T PT 2442832 E PT2442832 E PT 2442832E
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- treatment
- methods
- multiple sclerosis
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2442832E true PT2442832E (pt) | 2014-11-11 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107897886T PT2442832E (pt) | 2009-06-16 | 2010-06-16 | Composições e métodos para tratamento da esclerose múltipla |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (https=) |
| EP (1) | EP2442832B1 (https=) |
| JP (1) | JP5646617B2 (https=) |
| CN (1) | CN102458476B (https=) |
| AU (1) | AU2010260585B2 (https=) |
| BR (1) | BRPI1009606A2 (https=) |
| CA (1) | CA2688766C (https=) |
| CY (1) | CY1115714T1 (https=) |
| DK (1) | DK2442832T3 (https=) |
| ES (1) | ES2521565T3 (https=) |
| HR (1) | HRP20141035T1 (https=) |
| IL (1) | IL216993A (https=) |
| IN (1) | IN2012DN00167A (https=) |
| MX (1) | MX2011013661A (https=) |
| NZ (1) | NZ577731A (https=) |
| PL (1) | PL2442832T3 (https=) |
| PT (1) | PT2442832E (https=) |
| SI (1) | SI2442832T1 (https=) |
| SM (1) | SMT201400165B (https=) |
| WO (1) | WO2010147484A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009123480A1 (en) * | 2008-04-01 | 2009-10-08 | Virionyx Corporation Ltd | Anti-infective agents and uses thereof |
| HUE050713T2 (hu) * | 2010-10-25 | 2020-12-28 | Biogen Ma Inc | Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HUE071047T2 (hu) | 2016-08-31 | 2025-07-28 | Mapi Pharma Ltd | Glatiramer-acetátot tartalmazó depórendszerek |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| CA3099946A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| WO2020010221A1 (en) * | 2018-07-03 | 2020-01-09 | University Of Florida Research Foundation, Inc. | Microparticle systems and their use for the treatment of multiple sclerosis |
| US20230190570A1 (en) * | 2020-06-22 | 2023-06-22 | Otivio As | Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327896C (zh) * | 1996-10-10 | 2007-07-25 | 探针国际公司 | 治疗病毒感染的组合物及方法 |
| JP2008505130A (ja) * | 2004-07-01 | 2008-02-21 | ケベンハウンス・ウニヴェルジテート | レプトスピラ属感染の治療による多発性硬化症の治療及び予防方法 |
| US8603978B2 (en) * | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en not_active Ceased
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2014
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2442832A4 (en) | 2013-07-03 |
| IN2012DN00167A (https=) | 2015-04-17 |
| US20100317589A1 (en) | 2010-12-16 |
| BRPI1009606A2 (pt) | 2016-10-11 |
| HK1167101A1 (en) | 2013-02-01 |
| CY1115714T1 (el) | 2017-01-25 |
| CA2688766C (en) | 2015-06-30 |
| MX2011013661A (es) | 2012-05-22 |
| AU2010260585B2 (en) | 2013-02-21 |
| PL2442832T3 (pl) | 2015-01-30 |
| WO2010147484A8 (en) | 2012-07-19 |
| JP2012530132A (ja) | 2012-11-29 |
| AU2010260585A1 (en) | 2012-01-19 |
| SMT201400165B (it) | 2015-01-15 |
| CA2688766A1 (en) | 2010-12-16 |
| DK2442832T3 (da) | 2014-11-10 |
| ES2521565T3 (es) | 2014-11-12 |
| HRP20141035T1 (hr) | 2014-12-19 |
| EP2442832A1 (en) | 2012-04-25 |
| NZ577731A (en) | 2010-08-27 |
| EP2442832B1 (en) | 2014-08-06 |
| AU2010260585A8 (en) | 2012-06-14 |
| JP5646617B2 (ja) | 2014-12-24 |
| CN102458476B (zh) | 2014-08-20 |
| WO2010147484A1 (en) | 2010-12-23 |
| IL216993A (en) | 2016-03-31 |
| CN102458476A (zh) | 2012-05-16 |
| IL216993A0 (en) | 2012-02-29 |
| SI2442832T1 (sl) | 2014-12-31 |
| US8389479B2 (en) | 2013-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2442832E (pt) | Composições e métodos para tratamento da esclerose múltipla | |
| BR112012004979A2 (pt) | composições para o tratamento de semente e métodos | |
| PT2496691T (pt) | Composições de nucleases terapêuticas e métodos | |
| PT2367561E (pt) | Composições e métodos para o tratamento da doença celíaca | |
| BR112013019732A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| BRPI0924440A2 (pt) | aparelho para restauração óssea da espinha e métodos de utilização | |
| EP2515946A4 (en) | NANOCONJUGATE AND NANOCONJUGATE FORMULATIONS | |
| BR112013013025A2 (pt) | composições i-i e produtos e usos desta | |
| DK2419670T3 (da) | Leveringsmetode og sammensætninger | |
| BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
| BRPI0911612A2 (pt) | composições e métodos para o tratamento da esclerose múltipla. | |
| PT2512502T (pt) | Métodos e composições para supressão de tumores | |
| ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BR112014006321A2 (pt) | composições de wnt e usos terapêuticos de tal composição | |
| PT2830654T (pt) | Métodos e composições para tratamento de uma inflamação | |
| EP2635282A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF MYELOFIBROSIS | |
| BR112014006291A2 (pt) | composição e utilização da composição | |
| BRPI1007600A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
| PT2205720T (pt) | Composições para tratamento de esclerose múltipla | |
| BRPI1008326A2 (pt) | Composições e métodos para controlar nanatódeos | |
| EP2544655A4 (en) | COMPOSITIONS AND METHOD FOR SKIN TREATMENT | |
| PT2427193T (pt) | Utilização de inibidores da pde7 para o tratamento de distúrbios do movimento | |
| PL3400958T3 (pl) | Kompozycje i metody leczenia celiakii | |
| HRP20180748T1 (hr) | Postupak i mješavina za obradu metalnih površina |